Ryo Atsumi

2.7k citations

39 papers · 2.1k indexed · 1 hit paper · h-index 18

Oncology top 2%
Molecular Biology top 10%
Radiology, Nuclear Medicine and Imaging top 5%
Pulmonary and Respiratory Medicine top 10%
Pharmacology top 2%

Co-authors: Hideo Hakusui Wataru Suzuki Shingo Arakawa Masako Soma Tetsuo Aida Osamu Okazaki Yusuke Ogitani Yuki Abe
Topics: Cancer therapeutics and mechanisms (18 papers)Cancer Treatment and Pharmacology (13 papers)Pharmacogenetics and Drug Metabolism (6 papers)
Cited by: Oncology Pharmacology Radiology, Nuclear Medicine and Imaging
Journals: Blood Clinical Cancer Research Annals of Oncology
Partner nations: Japan Germany United Kingdom

In The Last Decade

Ryo Atsumi

37 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

2016 767 citations Yusuke Ogitani, Tetsuo Aida et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Ryo Atsumi

Since Specialization

Citations

This map shows the geographic impact of Ryo Atsumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Atsumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Atsumi more than expected).

Fields of papers citing papers by Ryo Atsumi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Atsumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Atsumi. The network helps show where Ryo Atsumi may publish in the future.

Co-authorship network of co-authors of Ryo Atsumi

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Atsumi. A scholar is included among the top collaborators of Ryo Atsumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Atsumi. Ryo Atsumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1breakdown → 2016 ·Clinical Cancer Research ·Yusuke Ogitani,Tetsuo Aida,Katsunobu Hagihara,Junko Yamaguchi,Chiaki Ishii,Naoya Harada,Masako Soma,Hiromi Okamoto,Masataka Oitate,Shingo Arakawa,Takehiro Hirai,Ryo Atsumi,Takashi Nakada,Ichiro Hayakawa,Yuki Abe,Toshinori Agatsuma	767
2	Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice 2009 ·Archives of Toxicology ·Shinji Shimizu,Ryo Atsumi,(unknown),Masaru Iwasaki,Takanori Aoki,Chiho Ono,Takashi Izumi,Kenichi Sudo,Osamu Okazaki	57
3	A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent Binding 2009 ·Drug Metabolism and Disposition ·Shintaro Nakayama,Ryo Atsumi,Hideo Takakusa,Yoshimasa Kobayashi,Atsushi Kurihara,Yoko Nagai,Daisuke Nakai,Osamu Okazaki	175
4	Metabolism of Ticlopidine in Rats: Identification of the Main Biliary Metabolite as a Glutathione Conjugate of Ticlopidine S-Oxide 2009 ·Drug Metabolism and Disposition ·Shinji Shimizu,Ryo Atsumi,(unknown),Yuko Fujimaki,Kenichi Sudo,Osamu Okazaki	27
5	Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS 2005 ·Journal of Chromatography B ·Toshihiro Oguma,(unknown),Fleur Gaudette,(unknown),(unknown),Ryo Atsumi	2
6	New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 5 2004 ·Bioorganic & Medicinal Chemistry Letters ·Yasuyuki Takeda,Kouichi Uoto,Michio Iwahana,Takeshi Jimbo,(unknown),Ryo Atsumi,Chiho Ono,Noriko Tanaka,Hirofumi Terasawa,Tsunehiko Soga	2
7	Validation study of a method for assaying DE‐310, a macromolecular carrier conjugate containing an anti‐tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry 2004 ·Biomedical Chromatography ·Toshihiro Oguma,Hiroshi Morikawa,(unknown),Ryo Atsumi	4
8	Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer 2004 ·Annals of Oncology ·Patrick Schöffski,(unknown),Gernot Beutel,O. Bolte,D. Otto,Melanie Hofmann,Arnold Ganser,(unknown),Peter Cheverton,J. Wanders,Toshihiro Oguma,Ryo Atsumi,(unknown)	48
9	Absorption, Distribution, and Excretion of DJ-927, a Novel Orally Effective Taxane, in Mice, Dogs, and Monkeys 2004 ·Biological and Pharmaceutical Bulletin ·Chiho Ono,(unknown),Ryo Atsumi	20
10	New highly active taxoids from 9β-Dihydrobaccatin-9,10-acetals. Part 4 2003 ·Bioorganic & Medicinal Chemistry ·Yasuyuki Takeda,Kouichi Uoto,Jun Chiba,Takao Horiuchi,Michio Iwahana,Ryo Atsumi,Chiho Ono,Hirofumi Terasawa,Tsunehiko Soga	14
11	Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices 2003 ·Journal of Chromatography B ·Otto Soepenberg,(unknown),Jaap Verweij,Ryo Atsumi,Alex Sparreboom	7
12	Establishment and functional characterization of an in vitro model of the blood–brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes 2001 ·European Journal of Pharmaceutical Sciences ·Pieter J. Gaillard,(unknown),(unknown),Ivanov Aa,Ryo Atsumi,Helena Engman,(unknown),Albertus G. de Boer,D. D. Breimer	267
13	A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium 1996 ·Annals of Oncology ·S. Gail Eckhardt,Howard A. Burris,John R. Eckardt,Geoffrey R. Weiss,Gladys Rodriguez,(unknown),David Rinaldi,Robert A. Barrington,(unknown),Kazuko Masuo,K Sudo,Ryo Atsumi,Toshihiro Oguma,(unknown),Suzanne M. Fields,Leslie Smetzer,Daniel D. Von Hoff	34
14	Metabolism of Irinotecan to SN-38 in a Tissue-Isolated Tumor Model. 1995 ·Biological and Pharmaceutical Bulletin ·Ryo Atsumi,Osamu Okazaki,Hideo Hakusui	17
15	Pharmaceutical and biological properties of doxorubicin encapsulated in liposomes (L‐ADM): The effect of repeated administration on the systemic phagocytic activity and pharmacokinetics 1995 ·Biopharmaceutics & Drug Disposition ·(unknown),Hiroshi Kikuchi,Norio Suzuki,Ryo Atsumi,Masashi Aonuma,Yasuyoshi Kawato	7
16	Metabolic Activation of CPT-11, 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase. 1994 ·Biological and Pharmaceutical Bulletin ·T Satoh,Masakiyo Hosokawa,Ryo Atsumi,Wataru Suzuki,Hideo Hakusui,(unknown)	148
17	Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. 1992 ·PubMed ·Hirofumi Imoto,(unknown),(unknown),Ryo Atsumi,Yoshinobu Takakura,Hitomi Sezaki,(unknown)	30
18	Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion 1991 ·Xenobiotica ·Ryo Atsumi,Wataru Suzuki,Hideo Hakusui	90
19	Studies on the Metabolic Fate of CPT-11. (1): Pharmacokinetics in Rats following a Single Intravenous Dose. (1). 1991 ·Drug Metabolism and Pharmacokinetics ·Hideo Hakusui,Wataru Suzuki,Ryo Atsumi,(unknown),Yoshitaka Jin,(unknown),(unknown),(unknown),Yuko Watanabe	1
20	Biliary excretion of mitomycin C dextran conjugates in relation to physicochemical characteristics of carrier dextran. 1990 ·Journal of Pharmacobio-Dynamics ·Mitsuru Hashida,Ryo Atsumi,(unknown),(unknown),Yoshinobu Takakura,Hitoshi Sezaki	15

About Ryo Atsumi

Ryo Atsumi is a scholar working on Oncology, Pharmacology and Pharmacology, having authored 39 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (18 papers), Cancer Treatment and Pharmacology (13 papers) and Pharmacogenetics and Drug Metabolism (6 papers). The work is most often cited by research in Oncology (1.2k citations), Pharmacology (255 citations) and Radiology, Nuclear Medicine and Imaging (453 citations). Ryo Atsumi has collaborated with scholars based in Japan, Germany and United Kingdom. Frequent co-authors include Hideo Hakusui, Wataru Suzuki, Shingo Arakawa, Masako Soma, Tetsuo Aida, Osamu Okazaki, Yusuke Ogitani, Yuki Abe, Toshinori Agatsuma and Junko Yamaguchi. Their work appears in journals such as Blood, Clinical Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact